✦ LIBER ✦

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase2b Study of Ustekinumab, a Human Monoclonal Antibody to IL-12/23p40, in Patients With Moderately to Severely Active Crohn's Disease: Results Through Week 22 From the Certifi Trial

✍ Scribed by William J. Sandborn; Christopher Gasink; Long-Long Gao; Marion Blank; Jewel Johanns; Cynthia Guzzo; Bruce E. Sands; Stephen B. Hanauer; Stephan R. Targan; Paul J. Rutgeerts; Subrata Ghosh; Willem de Villiers; Remo Panaccione; Gordon R. Greenberg; Stefan Schreiber; Simon Lichtiger; Brian G. Feagan

Book ID: 119432290
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 145 KB
Volume: 140
Category: Article
ISSN: 0016-5085
DOI: 10.1016/s0016-5085(11)60443-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P300 Health related quality of life resu

✍ B. Feagan; C. Gasink; L.-L. Gao; M. Blank; J. Johanns; C. Guzzo; C.-F. Chiou; W. 📂 Article 📅 2012 🏛 Oxford University Press 🌐 English ⚖ 67 KB

Phase I, double-blind, randomized, place

Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease

✍ C. Janneke van der Woude; Pieter Stokkers; Ad A. van Bodegraven; Gert Van Assche 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 274 KB 👁 2 views

Background: NI-0401 is a fully human monoclonal antibody, which binds to the CD3 subunit of the T-cell receptor, causing modulation of T-cell activity. We investigated the safety and the ability to modulate the TCR-CD3 complex of NI-0401 in patients with active Crohn's disease (CD). Methods: A doub

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled trial of the human anti-TNF-α monoclonal antibody adalimumab for the induction of remission in patients with moderate to severely active Crohn’s disease

✍ Stephen Hanauer; Milan Lukáš; Donald MacIntosh; Paul Rutgeerts; William Sandborn 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 45 KB

493 Safety Profile and Signal of Efficac

493 Safety Profile and Signal of Efficacy of a Non-Fcr-Binding, Fully Human Anti-Cd3 Monoclonal Antibody in Patients with Moderate to Severe Crohn's Disease- Results of a Phase I/Iia, Double Blind, Placebo-Controlled, Randomized, Dose Escalation Study

✍ Christien J. van der Woude; Pieter C. Stokkers; Ad A. van Bodegraven; Gert A. Va 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 87 KB